| Name | Iniparib |
| Description | Iniparib (BSI-201) (BSI-201) , a PARP1 inhibitor, exhibits potency in triple-negative breast Y (TNBC). |
| Cell Research | Cells are exposed to various concentrations of BSI-201 for 5, and 9 days in the presence or absence of buthionine sulfoxamide (BSO). After treatment, cell proliferation is measured by CellTiter-Glo assay.(Only for Reference) |
| In vivo | In 855-2 cells, the combination of BSI-201 (120 μM) and buthionine sulfoximine induced cell death up to 95%, which was similar to the effect on other human tumor cells. In E-ras 20 cells, BSI-201 inhibited cell growth, and its effect was enhanced 20-fold when combined with buthionine sulfoximine. BSI-201 (100 μM) inhibited the repair of ionizing radiation-induced single-strand breaks (SSBs) in human lymphocyte cell lines. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 14.6 mg/mL (49.99 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (11.3 mM), Sonication is recommended. DMSO : 85 mg/mL (291.07 mM), Sonication is recommended.
|
| Keywords | poly ADP ribose polymerase | PARP1 | PARP | NSC746045 | NSC 746045 | Iniparib | Inhibitor | inhibit | InfluenzaVirus | Influenza Virus | IND71677 | IND 71677 | BSI201 | BSI 201 |
| Inhibitors Related | Rifampicin | Acetylcysteine | α-Vitamin E | Molnupiravir | Nitazoxanide | Curcumin | Baicalein | Naringenin | Salcomine | Benzimidazole | Dihydromyricetin | β-Cyclodextrin |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |